Brii Biosciences Ltd. (OTC: BRIBY)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | -16.54 |
---|---|
% Price Change (last 13 weeks): | 4.19 |
% Price Change (last 26 weeks): | -55.33 |
% Price Change (last 52 weeks): | -68.38 |
% Price Change (year to date): | -55.48 |
Return on Equity (%): | -5.49 |
---|---|
Return on Assets (%): | -5.26 |
Return on Invested Capital (%): | -169.85 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | -28335.33 |
Operating Profit Margin (%): | -97245.71 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Brii Biosciences Ltd. engages in advancing therapies for significant infectious diseases and other illnesses which have significant public health burdens. The firm also focuses on developing therapies for infectious diseases and central nervous system diseases. The company was founded by Zhi Hong on December 8, 2017, and is headquartered in Beijing, China.
|
Brii Biosciences Ltd.
Zhongguancun Dongsheng, Building 7 1 North Yongtaizhuang Road 3rd Floor Haidian BE 100192 Phone: n/a Fax: n/a http://www.briibio.com |
Earnings (1year) ($): | -0.17 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 3.01 |
Cash Flow ($): | -0.15 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 2441.35 |
Price/Book (x): | 0.48 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 22.11 |
---|---|
Current Ratio (x): | 22.11 |
LT Debt/Equity (x): | 0.00 |
Total Debt/Equity (x): | 0.10 |